All AbMole products are for research use only, cannot be used for human consumption.
Bradykinin (bradykinin) is a vasodilator active peptide produced by the kinin-releasing enzyme-kinin system that modulates inflammation by causing vasodilation, increasing vascular permeability, and stimulating prostaglandin synthesis.
| Cell Experiment | |
|---|---|
| Cell lines | H9C2 cells |
| Preparation method | H9C2 cells, 24 hours after seeding in 12-well plates, were exposed to various concerntrations of H2O2 to induce DNA damage and senescence. After 2 hours, the medium was replaced with normal medium. BK with different kinds of concentrations was given 30 minutes before the induction of senescence. The B2R antagonist HOE-140 (1 µmol/l) and eNOS inhibitor Nω-methyl-L-arginine acetate salt (L-NAME) (10 µmol/l) were added 5 minutes before BK treatment, after which BK was added without replacing the medium. 24 hours after H2O2 treatment, H9C2 cells were harvested for senescence determination. At least 3 separate experiments were performed per treatment. |
| Concentrations | 1 pM-10 nM |
| Incubation time | 24 h |
| Animal Experiment | |
|---|---|
| Animal models | Male Swiss mice |
| Formulation | Physiological saline |
| Dosages | 2, 4 and 8 μg/mice |
| Administration | Intraplantar injection |
| Molecular Weight | 1060.21 |
| CAS Number | 58-82-2 |
| Form | Solid |
| Solubility (25°C) | Water ≥ 90 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] M Maurer, et al. New topics in bradykinin research
[3] R M Burch, et al. Bradykinin receptor antagonists
| Related Bradykinin Receptor Products |
|---|
| ELN 441958
ELN-441958 is a potent, neutral, competitive and selective oral bioavailable bradykinin B1 receptor antagonist with a Ki of 0.26 nM against native human bradykinin B1 receptor. |
| SSR240612
Treatment with the kinin B1 receptor antagonist, SSR240612, provided a protective effect against organ damage by interfering with multiple target functions, including the suppression of B1R-induced inflammation and platelet aggregation. |
| Icatibant (HOE 140) acetate
Icatibant (HOE-140) acetate is a potent and specific peptide antagonist of bradykinin B2 receptor, with IC50 value of 1.07 nM and Ki value of 0.798 nM, respectively. |
| Icatibant
Icatibant (HOE-140) is a potent and specific peptide antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively. |
| [Des-Arg9]-Bradykinin
[Des-Arg9]-Bradykinin is a Bradykinin (B1) receptor agonist that displays selectivity for B1 over B2 receptors. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
